PET-CT Response Evaluation Following Radiation Therapy ...

1 Radiation OncologyRO001-EB-XPET-CT Response Evaluation Following Radiation Therapy - established and Emerging ApplicationsAll Day Location: RO Community, Learning CenterParticipantsHelen Cliffe, MBBChir, BA, Leeds, United Kingdom (Presenter) Nothing to DiscloseMark Igra, MBBS, Leeds, United Kingdom (Abstract Co-Author) Nothing to DiscloseChirag Patel, FRCR, Oxford, United Kingdom (Abstract Co-Author) Nothing to DiscloseAndrew F. Scarsbrook, FRCR, Leeds, United Kingdom (Abstract Co-Author) Nothing to DiscloseTEACHING POINTS1.

2 To understand the rationale for using PET-CT to assess treatment Response in Radiation oncology 2. To illustrate establishedapplications of FDG PET-CT in assessment of efficacy of radical radiotherapy, chemo-radiotherapy and radionuclide Therapy 3. Tohighlight emerging PET-CT applications in Response assessment Following Radiation treatmentTABLE OF for PET-CT Response assessment in Radiation oncology2. Current uses of FDG PET-CT in treatment responsefollowing Radiation Therapy : head and neck cancer; oesophago-gastric carcinoma; rectal carcinoma; brain tumors3.

3 Emergingapplications of FDG PET-CT : cervical carcinoma; lung carcinoma; HPB tumours particularly pancreatic carcinoma and livermetastases (post selective internal radiotherapy treatment)4. Potential applications of non-FDG PET-CT : neuro-oncology; prostaticmalignancy; neuroendocrine malignancy5. Limitations of PET-CT The major teaching points are:a) Radiation Therapy is associatedwith a significant risk of disease ) PET-CT provides accurate non-invasive surrogate biomarkers of tumor Response ) FDG PET-CT has a role in treatment Response assessment Following radiotherapy in a variety of tumor types and canhelp guide patient ) Novel tracers show promise in a range of Lipoblastoma: Intensity Modulated Radiotherapy or Surgery?

4 All Day Location: RO Community, Learning CenterParticipantsMukul Roy, MD, MBBS, New Delhi, India (Presenter) Nothing to DiscloseRahul M. Nikam, MBBS, DMRD, Mumbai, India (Abstract Co-Author) Nothing to DiscloseTEACHING are rare benign tumors seen in infants and young children. Complete resection achieves optimal results,butrecurrence is growths can be treated with radiotherapy in surgically inaccessible sites/ in cases which wouldlead to mutilating OF CONTENTS/OUTLINE17 year boy presented with swelling on left side face extending to peri-orbital region and proptosis with no diminution in operated twice,in 2000 and May 2012 by wide local excision.

5 Histopathology had reported lipoblastoma. One week aftersurgery the swelling reported T1 hypointense /isointense/T2 hyperintense lobulated lesion involving leftmasseter muscle, insinuating ramus of mandible and pterygoid muscles. Similar lesion was seen at infra-orbital regioninvolving eyelids, inner and outer canthus infiltrating intraorbitally encasing eyeball,extraocular muscles and retrobulbar fat,extending to orbital apex encasing left optic extended to temporal fossa,temporalis muscle eroding zygoma and greaterwing of sphenoid measuring treated patient with Intensity Modulated Radiotherapy, 6 coplanar beam,24 segments to 50Gy/25 fractions, 2Gy/#/day keeping organs at risk below tolerance.

6 Seven months post radiotherapy he wasclinically stable with no dimunition of Cutaneous Melanoma. Guidelines in Diagnosis and Follow-upAll Day Location: RO Community, Learning CenterFDA Discussions may include off-label of MeritParticipantsClaudia L. Martinez Higueros, MMedSc, Colonia Puerta de Hierro, Spain (Presenter) Nothing to DiscloseJavier Pereda Rodriguez, Madrid, Spain (Abstract Co-Author) Nothing to DiscloseGema Sanchez del Peral Otero, MD, Madrid, Spain (Abstract Co-Author) Nothing to DiscloseJavier Gonzalez, Segovia, Spain (Abstract Co-Author) Nothing to DiscloseCarlos Oliva Fonte, Segovia, Spain (Abstract Co-Author) Nothing to DiscloseCris Eugenia Sibaja Castro, MSc, Madrid, Spain (Abstract Co-Author)

7 Nothing to DiscloseTEACHING POINTSA fter revising this exhibit, the learner will be able to :1. Follow a practical workflow for imaging cutaneous Identifyingthe most suitable imaging techniques for the initial assessment of early and advanced disease of cutaneous To utilizethe recomendations from the international updated guidelines to develop their own protocol for imaging cutaneous melanoma withintheir own OF a. American Journal Cancer Committee Staging for Cutaneous Melanoma Assessment b. NationalComprenhensive Cancer Network.

8 Recommendations for the clinical management and follow- up of Study Methods and Materials Results Discussion Protocol for Imaging Tests inthe diagnosis and follow-up of Cutaneous of Skull Base Lesions After Radiotherapy for Nasopharyngeal Carcinoma: A Comparative Studyof MR Imaging and PathologyAll Day Location: RO Community, Learning CenterFDA Discussions may include off-label Zhou, MS, BS, Guangzhou, China (Abstract Co-Author) Nothing to DiscloseSui-Qiao Huang, Guangzhou, China (Presenter) Nothing to DiscloseTEACHING POINTSThe main MRI features of skull base recurrence of NPC are as follows.

9 A slightly more intense signal than muscle on T2WI, anasymmetrically homogeneous appearance, isolated bone involvement, bone destruction that originates from the exterior, and peri-space fat a moderately intense signal on plain T1WI and obvious enhancement were visible, T2WI intensity is thekey to differentiate high activity lesions from recurrences. Skull base masses with obvious high signal intensity on T2WI aresuggestive of noncancerous lesions rather than and accurate diagnosis of skull base lesions and differentiation ofrecurrence from noncancerous lesions can guide the selection of therapeutic strategies for nasopharyngeal carcinoma patients whohave received OF CONTENTS/OUTLINEP urpose; Methods; Results.

10 Study of Beam Attenuation Correction Due to the 6-axis Corresponding Carbon FiberCouchtop(CFC) for LinacAll Day Location: RO Community, Learning CenterParticipantsKohei Iwamura, RT, Tokyo, Japan (Presenter) Nothing to DiscloseYusuke Ono, Tokyo Koutouku, Japan (Abstract Co-Author) Nothing to DiscloseKeigo Okabe, RT, Tokyo, Japan (Abstract Co-Author) Nothing to DiscloseMitsuyoshi Yasuda, PhD, Koto-Ku, Japan (Abstract Co-Author) Nothing to DiscloseToshiyuki Takahashi, Tokyo-To, Japan (Abstract Co-Author) Nothing to DiscloseSyougo Sai, Kanagawa, Japan (Abstract Co-Author)